Loading…
Vaxcyte, Inc. is projected to rise to $58.23 by 2027, a +14% move from its current price of $51.02. PCVX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $49.62 | $51.01 | $52.43 | -0.02% |
| May 30 | $49.05 | $51.00 | $53.02 | -0.05% |
| May 31 | $48.61 | $50.99 | $53.47 | -0.07% |
| Jun 1 | $48.24 | $50.97 | $53.86 | -0.09% |
| Jun 2 | $47.92 | $50.96 | $54.20 | -0.11% |
| Jun 3 | $47.63 | $50.95 | $54.50 | -0.14% |
| Jun 4 | $47.36 | $50.94 | $54.79 | -0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $47.36 | $50.94 | $54.79 | -0.16% |
| Week 2 | $45.88 | $50.86 | $56.37 | -0.32% |
| Week 3 | $44.76 | $50.78 | $57.60 | -0.48% |
| Week 4 | $43.82 | $50.70 | $58.64 | -0.64% |
| Week 5 | $43.01 | $50.61 | $59.57 | -0.79% |
| Week 6 | $42.28 | $50.53 | $60.40 | -0.95% |
| Week 7 | $41.61 | $50.45 | $61.17 | -1.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX is the stock ticker for Vaxcyte, Inc. It is currently priced at $51.02 with a market capitalization of $7.37B and is ranked 1072.
The near-term outlook uses a 2026 forecast where the average price is $51.02, with a low of $44.85 and a high of $67.38 and a neutral sentiment.
Longer-range forecasts show rising averages and expanding ROI, with the 2030 average at $80.29 and the 2050 average at $361.01, accompanied by a strong cumulative rise in ROI through 2050.
A major floor 24.9% below — a decisive break under it would weaken the trend.
The nearest floor, 7.5% below — buyers have tended to step in here.
The nearest ceiling, 22.2% above — a clean break opens room to run.
A major ceiling 34.6% above — clearing it would confirm fresh momentum.
Key PCVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $48.60 | Buy | $49.62 | Buy |
| MA 10 | $50.04 | Buy | $50.31 | Buy |
| MA 20 | $52.78 | Sell | $52.32 | Sell |
| MA 50 | $56.26 | Sell | $54.70 | Sell |
| MA 100 | $55.19 | Sell | $53.79 | Sell |
| MA 200 | $47.67 | Buy | $52.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.95 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -37.93 | Neutral |
| Williams %R (14) | -45.62 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | -3.75 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 54.38 | Neutral |
| TRIX (15) | -0.58 | Sell |
| Awesome (5,34) | -7.57 | Sell |
| Ultimate (7,14,28) | 39.30 | Neutral |
| Momentum (10) | -3.01 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 48.73 | Buy |
| ADX (14) | 24.09 | Sell |
| ATR (14) | 1.26 | Info |
Technical picture for the last 30 days shows a bullish bias.
RSI(14) is 40, with the 50-day simple moving average (SMA50) at $56.26 and the 200-day simple moving average (SMA200) at $47.67. Support is noted at $47.17 and resistance at $62.35. The 30-day price range spans from $42.55 to $61.17.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.85 | $51.02 | $67.38 | 0% | Neutral | |
| $46.14 | $58.23 | $77.86 | +14% | Neutral | |
| $46.25 | $59.98 | $83.13 | +18% | Neutral | |
| $51.95 | $68.93 | $98.30 | +35% | Bullish | |
| $59.29 | $80.29 | $117.28 | +57% | Bullish | |
| $65.45 | $90.30 | $134.71 | +77% | Bullish | |
| $78.16 | $109.72 | $166.81 | +115% | Bullish | |
| $82.82 | $118.18 | $182.78 | +132% | Bullish | |
| $81.65 | $118.33 | $185.93 | +132% | Bullish | |
| $88.25 | $129.80 | $206.97 | +154% | Bullish | |
| $130.34 | $205.09 | $347.83 | +302% | Bullish | |
| $204.20 | $361.01 | $669.93 | +608% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $44.85 | $51.02 | $59.99 | +0.00% |
| June 2026 | $43.02 | $50.53 | $60.77 | -0.96% |
| July 2026 | $42.18 | $49.97 | $60.92 | -1.11% |
| August 2026 | $43.24 | $51.57 | $63.52 | +3.19% |
| September 2026 | $43.87 | $52.61 | $65.35 | +2.02% |
| October 2026 | $42.94 | $51.74 | $64.78 | -1.64% |
| November 2026 | $42.84 | $51.86 | $65.35 | +0.22% |
| December 2026 | $43.70 | $53.13 | $67.38 | +2.45% |
Click any year to see its month-by-month PCVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Vaxcyte, Inc.'s 2026 outlook centres on $51.02, within a $44.85 to $67.38 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PCVX could reach as high as $77.86, with a base case around $58.23 and support toward $46.14 — roughly +14% from $51.02. A consolidation phase looks the most probable path here.
Expect PCVX to range from $46.25 to $83.13 through 2028. The $59.98 average target implies a +18% move from current prices. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
The PCVX price prediction for 2029 points to an average of $68.93 (low $51.95, high $98.30) — a potential gain of +35% on today's $51.02. Buyers look set to stay in control over this stretch.
In 2030, PCVX is projected to trade between $59.29 and $117.28, averaging $80.29 — a potential gain of +57% from today's $51.02. That is up +16% on the projected 2029 average. Momentum favours further upside here.
Vaxcyte, Inc.'s 2031 outlook centres on $90.30, within a $65.45 to $134.71 range. That is up +12% on the projected 2030 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PCVX could reach as high as $166.81, with a base case around $109.72 and support toward $78.16 — roughly +115% from $51.02. Momentum favours further upside here.
Expect PCVX to range from $82.82 to $182.78 through 2033. The $118.18 average target implies a +132% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PCVX price prediction for 2034 points to an average of $118.33 (low $81.65, high $185.93) — a potential gain of +132% on today's $51.02. Momentum favours further upside here.
In 2035, PCVX is projected to trade between $88.25 and $206.97, averaging $129.80 — a potential gain of +154% from today's $51.02. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Vaxcyte, Inc.'s 2040 outlook centres on $205.09, within a $130.34 to $347.83 range. That is up +58% on the projected 2035 average. That marks a +302% change versus current levels. Momentum favours further upside here.
By 2050, PCVX could reach as high as $669.93, with a base case around $361.01 and support toward $204.20 — roughly +608% from $51.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCVX today (≈ 19.600157 PCVX) could be worth
$7,075.83
+$6,075.83 (+608%) by 2050 · US Dollar
Based on the average projected PCVX price of $361.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCVXwould be worth at today's price.
$1,000 invested in PCVX on May 27, 2025 (≈ 31.515916 PCVX) would be worth
$1,607.94
+$607.94 (+60.8%) today · 1.61× · US Dollar
Based on a PCVX entry price of $31.73 vs. today's $51.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $47.17 | $1,081.62 | +8.2% |
| 1 month ago | $59.72 | $854.32 | -14.6% |
| 3 months ago | $60 | $850.33 | -15.0% |
| 6 months ago | $49.61 | $1,028.42 | +2.8% |
| 1 year ago | $31.73 | $1,607.94 | +60.8% |
| All time (5.0y) ago | $21.11 | $2,416.86 | +141.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCVX forecast.
Our base-case forecast reaches $100.00 around 2032.
Implied market cap at $100.00: $14.44B
The multi-year forecast paints a clear upward trajectory, with the 2030 average price projected at $80.29 and the 2040 average at $205.09, rising further to $361.01 by 2050.
Projected ROI climbs from 0 in 2026 to 57.4 in 2030, then 302 in 2040 and 607.6 in 2050, with consistent bullish sentiment from 2027 onward.
Max price forecasts exceed $100 beginning in 2032, with 2032 max $166.81, 2033 max $182.78, 2034 max $185.93, and 2035 max $206.97, followed by $347.83 in 2040 and $669.93 in 2050. The volatility level is high, with annualized volatility at 50%.
Tap a question to reveal the answer.
The forecast shows an average price of $80.29 with a range from $59.29 to $117.28 and a 57.4 (ROI) for 2030.
Forecasts show rising averages and positive ROI in multiple years, including 14.1 in 2027, 17.6 in 2028, 35.1 in 2029, 57.4 in 2030, 77 in 2031, 115 in 2032, 131.6 in 2033, 131.9 in 2034, and 154.4 in 2035, culminating in 302 in 2040 and 607.6 in 2050.
Yes. The max forecast price exceeds $100 starting in 2032 (max $166.81), with higher max values in 2033 ($182.78), 2034 ($185.93), 2035 ($206.97), 2040 ($347.83), and 2050 ($669.93).
Current price is $51.02 and market cap is $7.37B.
The 30-day range is $42.55 to $61.17. Current price is $51.02 with sentiment BULLISH; RSI(14) is 40, SMA50 is $56.26, SMA200 is $47.67, with support at $47.17 and resistance at $62.35.
Vaxcyte, Inc. Community Discussion
0Share your Vaxcyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.